Healthcare Business - Page 2

Aldeyra Stumbles Over Mid-Stage Clinical Results

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) saw its shares slide on Wednesday after the company gave an update from its mid-stage trial of topical ocular ADX-102 in patients with allergic conjunctivitis. ...
Read Full Story »

Alexion Pharmaceuticals Adds New CFO From Biogen

Shares of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) saw a handy gain early on Wednesday after the company announced that there would be changes in its leadership. The company announced that ...
Read Full Story »

How Omeros Won Big on This FDA Approval

Omeros Corp. (NASDAQ: OMER) saw its shares make a handy gain on Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation ...
Read Full Story »

Acceleron Pharma Slides on Missed Mid-Stage Results

Acceleron Pharma Inc. (NASDAQ: XLRN) saw its shares droop early on Tuesday after the firm offered an update from its mid-stage trial in advanced renal cell carcinoma (RCC). Specifically, Acceleron ...
Read Full Story »

Why Coherus Biosciences Shares Are Crashing

Coherus Biosciences Inc. (NASDAQ: CHRS) saw its shares crater on Monday after the company announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration ...
Read Full Story »

4 Red-Hot Pharmaceutical and Biotechs Highlight Jefferies Top Stocks to Buy

Health care is a sector that has been good to investors so far this year, and some of the top pharmaceutical and biotech companies have posted outstanding results. While there ...
Read Full Story »

Short Interest Surges in Major Biotechs

The short interest data are out for the most recent settlement date, May 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Short Sellers Grow More Selective on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Dova Pharma Files for IPO

Dova Pharmaceuticals recently filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company did not mention any pricing details in ...
Read Full Story »

Who Wins From Endo’s Opana Getting Pulled From the Market

In an unprecedented move, the U.S. Food and Drug administration (FDA) requested that Endo International PLC (NASDAQ: ENDP) remove its Opana ER from the market. Ultimately, the agency held concerns ...
Read Full Story »

FDA Shelves Endo Pharma Amid Opioid Abuse

Opioid addiction is a serious problem in the United States and globally, one that spans all demographics. According to a recent study, drug overdose is the leading cause of accidental ...
Read Full Story »

Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial

Shares of Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) saw a hand gain early on Friday after the company reported top-line results from its late-stage trial in type-1 diabetes. Specifically, Lexicon announced ...
Read Full Story »

Inovio Pharmaceuticals Kicks Off Late-Stage HPV Clinical Trial

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares posted a solid gain on Thursday after the company announced that it was beginning its late-stage trial of its treatment for cervical dysplasia caused ...
Read Full Story »

Valeant Pharmaceuticals Plans to Sell iNova Segment

Valeant Pharmaceuticals International Inc. (NYSE: VRX) shares made a solid gain on Thursday after the company announced the sale of its iNova Pharmaceutical business. Ultimately, Valeant will sell iNova for ...
Read Full Story »

NewLink Genetics Sinks After Regaining Licensing Rights for Its Cancer Treatment

NewLink Genetics Corp. (NASDAQ: NLNK) shares backed off early on Thursday after the company announced that it had regained the rights to GDC-0919 across multiple cancer designations. Newlink shareholders are ...
Read Full Story »